Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance - ACCEL-RESISTANCE

Description:

Recent studies have demonstrated a high post-treatment platelet activity (HPPR) with clopidogrel as predictive of adverse outcomes after percutaneous coronary intervention (PCI), including stent thrombosis. HPPR can partially be overcome with a higher loading (LD) or maintenance dose (MD) of clopidogrel. The ACCEL-RESISTANCE trial sought to investigate whether triple antiplatelet therapy, with the addition of cilostazol, would be associated with greater platelet inhibition in patients with HPPR,...